Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound
JE · Effective Nov 12, 2023
23 active Medicare policies list M76.52, and 4 commercial payer policies list it. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
JE · Effective Nov 12, 2023
JF · Effective Nov 12, 2023
JJ · Effective Apr 30, 2023
JM · Effective Apr 30, 2023
JE · Effective Oct 1, 2015
JF · Effective Oct 1, 2015
J6 · Effective Oct 1, 2015
JK · Effective Oct 1, 2015
4 policies from 1 payer
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
| Policy | Effective | Status of M76.52 |
|---|---|---|
| Allograft Transplants of the Extremities | Nov 20, 2023 | Covered |
| Autologous Skeletal Myoblast/Mononuclear Bone Marrow Cell Transplantation | Aug 30, 2023 | Covered |
| Blood and Adipose Tissue Derived Products for Selected Indications | Oct 26, 2023 | Covered |
| Prolotherapy and Sclerotherapy | Apr 11, 2023 | Covered |
J6
J6 · Effective Oct 1, 2015
JK · Effective Oct 1, 2015
National · Effective Oct 1, 2026
National · Effective Oct 1, 2026
J6 · Effective Oct 1, 2026
National · Effective Oct 1, 2025
J5 · Effective Oct 1, 2026
J9 · Effective Jan 1, 2026
JL · Effective Jan 1, 2026
National · Effective Oct 1, 2026
J6 · Effective Oct 1, 2026
National · Effective Oct 1, 2026
J6 · Effective Oct 25, 2026